Education
About Us
Working with TipRanks
Follow Us
MetaVia (MTVA)
NASDAQ:MTVA
MTVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.63 - $5.30
Previous CloseN/A
Volume36.62K
Average Volume (3M)468.70K
Market Cap
$14.34M
Enterprise Value-$9.40M
Total Cash (Recent Filing)$16.02M
Total Debt (Recent Filing)$136.00K
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Aug 19, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding19,588,350
10 Day Avg. Volume161,248
30 Day Avg. Volume468,705
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-1.18
Enterprise Value/Market Cap-0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$7.50Price Target Upside927.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
MetaVia News
PremiumCompany Announcements
MetaVia Faces Nasdaq Delisting Notice for Low Stock Price
PremiumCompany Announcements
MetaVia Reports Progress in Obesity and MASH Treatments
PremiumCompany Announcements
MetaVia Updates Corporate Presentation on DA-1726 Progress
PremiumCompany Announcements
MetaVia Completes $10 Million Private Placement
PremiumCompany Announcements
MetaVia Unveils Promising DA-1241 Trial Results
Bulls Say, Bears Say
Bulls Say
Financial OutlookThe company expects to have financial runway into 2026, following recent equity financing.
Safety And TolerabilityThe safety profile of DA-1726 is differentiated and potentially better than other options, with no treatment-related discontinuations, and GI events being only transient and mild.
Weight Loss PotentialThe interim dataset is seen as highly encouraging evidence of DA-1726's weight loss potential and benign safety profile, positioning it as a potential best-in-class weight loss therapy.
Bears Say
Market CompetitionShares of MTVA are under pressure, down ~20%, stemming from a combination of misunderstanding of the data itself and activity in the obesity/metabolic space from Merck which is also pressuring Viking shares.
Stock Market ReactionMTVA shares were down 56% on the news, which is viewed as an overreaction on what was only an early-stage study.
Options Prices
Currently, No data available
---
Ownership Overview
54.54% Insiders
0.93% Mutual Funds
5.21% Other Institutional Investors
38.68% Public Companies and
Individual Investors
MTVA FAQ
What was MetaVia’s price range in the past 12 months?
MetaVia lowest stock price was $0.63 and its highest was $5.30 in the past 12 months.
What is MetaVia’s market cap?
MetaVia’s market cap is $14.34M.
When is MetaVia’s upcoming earnings report date?
MetaVia’s upcoming earnings report date is Aug 19, 2025 which is in 63 days.
How were MetaVia’s earnings last quarter?
MetaVia released its earnings results on May 14, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.39 by $0.03.
Is MetaVia overvalued?
According to Wall Street analysts MetaVia’s price is currently Undervalued.
Does MetaVia pay dividends?
MetaVia does not currently pay dividends.
What is MetaVia’s EPS estimate?
MetaVia’s EPS estimate is -0.24.
How many shares outstanding does MetaVia have?
MetaVia has 19,588,350 shares outstanding.
What happened to MetaVia’s price movement after its last earnings report?
MetaVia reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.39. Following the earnings report the stock price went up 1.493%.
Which hedge fund is a major shareholder of MetaVia?
Currently, no hedge funds are holding shares in MTVA
Company Description
MetaVia
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
MTVA Stock 12 Month Forecast
Average Price Target
$7.50
▲(927.40%Upside)
Technical Analysis
Palatin Technologies
―
Evogene
―
TransCode Therapeutics
―
Silexion Therapeutics
―
Apollomics
―